.png){kind=icon}
返回
Thalassaemia
.png){kind=icon}
PRE
AI
DOI：10.1016/S0140-6736(22)00536-0.png)
.png){kind=icon}
原文求助.png){kind=icon}
分享.png){kind=icon}
收藏
摘要
En 中文
Thalassaemia is a diverse group of genetic disorders with a worldwide distribution affecting globin chain synthesis. The pathogenesis of thalassaemia lies in the unbalanced globin chain production, leading to ineffective erythropoiesis, increased haemolysis, and deranged iron homoeostasis. The clinical phenotype shows heterogeneity, ranging from close to normal without complications to severe requiring lifelong transfusion support. Conservative treatment with transfusion and iron chelation has transformed the natural history of thalassaemia major into a chronic disease with a prolonged life expectancy, albeit with co-morbidities and substantial disease burden. Curative therapy with allogeneic haematopoietic stem cell transplantation is advocated for suitable patients. The understanding of the pathogenesis of the disease is guiding therapeutic advances. Novel agents have shown efficacy in improving anaemia and transfusion burden, and initial results from gene therapy approaches are promising. Despite scientific developments, worldwide inequality in the access of health resources is a major concern, because most patients live in underserved areas.
Keyword:
STEM-CELL TRANSPLANTATION
BETA-THALASSEMIA
IRON OVERLOAD
INEFFECTIVE ERYTHROPOIESIS
TRANSFUSED PATIENTS
PEDIATRIC-PATIENTS
ALPHA-THALASSEMIA
CHELATION-THERAPY
MYOCARDIAL IRON
GLOBIN GENE
期刊
IF:
88.5
论文数:
5.4W
被引数:
34.8W
机构
引用论文
分享收藏Cas9 activates the p53 pathway and selects for p53-inactivating mutationsCas9激活p53通路并选择p53-inactivating突变.png)
NATURE GENETICS
OAAI
NATURE GENETICSIF31.8
OAAI分享收藏The pyruvate kinase activator mitapivat reduces hemolysis and improves anemia in a β-thalassemia mouse model丙酮酸激酶激活剂mitapivat在 β-地中海贫血小鼠模型中减少溶血并改善贫血
OAAI
OAAI分享收藏Survival and causes of death in 2,033 patients with non-transfusion-dependent β-thalassemiaHAEMATOLOGICAOAAI
HAEMATOLOGICAIF7.9
OAAI分享收藏
查看更多内容